Fort Collins, Colo. -- CSU, NeoTrex and the Veterinary Diagnostic Institute (VDxI) inked a deal to develop a new diagnostic test to detect canine hemangiosarcoma.
Fort Collins, Colo.
-- A new diagnostic test to detect canine hemangiosarcoma is in the works through a collaboration with Colorado State University (CSU) Research Foundation, NeoTREX and the Veterinary Diagnostics Institute (VDxI) of Irvine, Calif.Officials signed a license agreement this week to develop a biomarker assay to detect this form of cancer in dogs. The technology, co-invented by faculty at CSU's Animal Cancer Center, a member of CSU's Cancer Supercluster, and investigators at VDxI, will be used to detect levels of the enzyme thymidine kinase in dogs using a simple blood test, the university reports today.Hemangiosarcoma occurs most often in large-breed dogs older 8 years of age, often resulting in internal hemorrhage leading to death. Other than ultrasound, there are no other prognostic methods to detect hemangiosarcoma in dogs, university officials add.VDxI, a reference laboratory, plans to develop the technology and co-market with another technology to detect lymphoma in dogs. NeoTREX is the enterprise arm of the Cancer Supercluster.
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen